Is BPC-157 the same as a body protection compound?

BPC-157 is a specific 15-amino-acid synthetic peptide derived from a fragment of a larger protein called body protection compound. They are not the same thing: the parent protein is much larger, and BPC-157 represents only a portion of its sequence.

Has BPC-157 been tested in human clinical trials?

Large, well-controlled human clinical trials of BPC-157 for tissue repair or the other indications commonly discussed in fitness contexts had not been published in peer-reviewed literature as of 2024. Most published research involves rodent models from a concentrated group of researchers at the University of Zagreb.

Is BPC-157 banned by WADA?

Yes. BPC-157 is named on the WADA Prohibited List under section S2 and is banned at all times for athletes subject to anti-doping rules.

How does BPC-157 relate to TB-500?

Both are research peptides discussed in the context of tissue repair, but they are structurally unrelated. BPC-157 is derived from a gastric juice protein and is 15 amino acids long. TB-500 is related to thymosin beta-4, an actin-binding protein found throughout the body. They are sometimes sold together as a blend.

Healing & Recovery

BPC-157

Synthetic 15-amino-acid peptide derived from a fragment of a gastric juice protein.

Also known as: Body protection compound 157, Pentadecapeptide BPC

Published: April 17, 2026•Updated: April 17, 2026

Research use only. This page is an informational reference about a compound that may be available as a research chemical. Material sold for research is not cleared for human administration and is not a substitute for medical advice or an approved medication. See safety notes below.

BPC-157 is a synthetic pentadecapeptide whose sequence is derived from a partial fragment of body protection compound, a protein found in human gastric juice. It has been studied primarily in preclinical animal models by researchers at the University of Zagreb, with a large body of rodent data but very limited human clinical trial evidence. It remains unapproved and is classified as a research chemical.

Key facts

Class: Synthetic pentadecapeptide (15 amino acid sequence)
Source: Partial fragment of body protection compound from human gastric juice
Regulatory status: Not approved by the FDA for any indication
WADA status: Prohibited at all times under S2 Peptide Hormones
Primary research focus: Tissue repair, gastrointestinal injury, angiogenesis in preclinical models

What is BPC-157?

BPC-157 stands for body protection compound 157. It is a synthetic peptide built from a 15-amino-acid sequence that corresponds to a partial fragment of a larger protein found in human gastric juice. That parent protein was identified in the early 1990s by researchers at the University of Zagreb, led by Predrag Sikiric, who have been the most prolific publishers on BPC-157 for more than three decades.

Despite the volume of published preclinical work, BPC-157 has not progressed through large-scale randomized human clinical trials for any of the indications most commonly discussed in athletic or recovery communities. It is available commercially as a research chemical intended for laboratory use only.

Mechanism of action

Researchers have proposed several mechanisms for BPC-157 based on cell culture and animal experiments. The picture is more complex than for approved drugs in this class, partly because no single receptor has been established as the primary target.

•Reported influence on nitric oxide signaling pathways in animal models of tissue injury
•Reported effects on vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression in preclinical studies
•Interactions with dopamine and serotonin receptor systems described in rodent behavioral and gastrointestinal research
•Reported effects on angiogenesis and collagen deposition in injured tissue in animal studies
•Proposed cytoprotective effects in gastric mucosa, consistent with its gastric origin

Research context

The published literature on BPC-157 spans decades and covers a wide range of animal models: gastrointestinal injury, bone and tendon repair, peripheral nerve damage, organ protection, and more. The common thread is that the researchers are largely a single group centered at the University of Zagreb, which makes independent replication across laboratories less established than for compounds with broader research communities.

Well-designed human clinical trials of BPC-157 for tissue repair indications are scarce. As of 2024, no large phase 2 or phase 3 trials had been published in peer-reviewed literature. The gap between the volume of preclinical publications and the absence of human trial evidence is notable when evaluating claims made about this compound in popular media.

Safety and regulatory context

The FDA has not approved BPC-157 for any indication. There is no established human safety database from controlled clinical trials, which means adverse effects, drug interactions, and dosing parameters in humans are not defined by regulated evidence.

The World Anti-Doping Agency lists BPC-157 on its Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and prohibits it at all times in and out of competition. Athletes subject to WADA rules face anti-doping consequences for use.

Material sold commercially as research-grade BPC-157 is unregulated and cannot be verified for identity or purity without independent analytical testing. It is intended strictly for laboratory use and is not cleared for human administration.

Research sourcing

BPC-157 is listed by our research partner, GLP1 Research Lab, which supplies lyophilized peptides for laboratory use. Listings include product identifiers relevant to research documentation.

View BPC-157 listing at GLP1 Research Lab

Affiliate partnership. Metabolic Playbook may earn a commission on purchases made through this link at no additional cost to the researcher.